🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Cellebrite expands federal reach with CyTech acquisition

EditorNatashya Angelica
Published 17/07/2024, 18:14
© Shlomi Yosef, Cellebrite PR
CLBT
-

TYSONS CORNER, Va. and PETAH TIKVA, Israel - Cellebrite (NASDAQ: CLBT), a digital investigative solutions provider, has announced the creation of Cellebrite Federal Solutions. This new arm of the company is designed to cater specifically to the U.S. federal government's needs, leveraging its AI-driven Case-to-Closure (C2C) platform.

The initiative includes the acquisition of cybersecurity and digital forensics firm Cyber Technology Services, Inc. (CyTech), and the appointment of four new independent directors with backgrounds in U.S. defense, cyber intelligence, software as a service (SaaS), and legal prosecution.

Cellebrite's expansion aims to enhance its services to U.S. justice, defense, intelligence, and other federal civilian agencies. The integration of CyTech's expertise and workforce is expected to complement Cellebrite's capabilities and support its growth in the federal sector. The financial terms of the CyTech acquisition have not been disclosed.

Erik Sachwitz, who has been leading Cellebrite's U.S. federal business since 2020, will head the new unit. In 2023, the U.S. federal government accounted for approximately 19% of Cellebrite’s annual recurring revenue in the public sector, marking a 21% increase from the previous year.

The newly appointed independent directors bring a diverse set of skills and experiences to the table. They include Lt. Gen. (ret.) Ken Tovo, Dr. Barry West, Mark Ferrer, and Barbara Grewe, each with a significant track record in their respective fields of special operations, technology, business, and law enforcement.

Cellebrite's CEO, Yossi Carmil, expressed enthusiasm for the venture and the enhanced support it will provide to federal government partners. The establishment of Cellebrite Federal Solutions and the pursuit of FedRAMP authorization for its SaaS offerings are strategic moves to meet the evolving needs of U.S. federal customers.

This development is part of Cellebrite's broader strategy to deepen its engagement with the federal market. As the company moves forward, it aims to leverage its enhanced capabilities and leadership to support the missions of its federal customers more effectively.

The information in this article is based on a press release statement from Cellebrite.

InvestingPro Insights

As Cellebrite (NASDAQ: CLBT) continues to focus on expanding its services within the U.S. federal government sector, the company's financial health and market performance provide valuable context for investors.

With a market capitalization of $2.48 billion, Cellebrite exhibits substantial size in the digital investigative solutions market. A key InvestingPro Tip to note is the company's impressive gross profit margins, which stood at a robust 87.79% over the last twelve months as of Q1 2024. Such high margins are indicative of the company's ability to manage costs effectively while maintaining premium pricing for its services.

Cellebrite's financial stability is further underscored by the fact that it holds more cash than debt on its balance sheet, an InvestingPro Tip that suggests a solid financial footing for strategic initiatives like the creation of Cellebrite Federal Solutions. Moreover, while the company has not been profitable over the last twelve months, analysts predict that Cellebrite will turn a profit this year, which could signal a positive shift in its financial trajectory.

Investors should also be aware that Cellebrite is trading near its 52-week high, with the price at 95.19% of this peak. The company has experienced a large price uptick over the last six months, with a total return of 46.54%. This performance reflects investor confidence and the market's response to Cellebrite's strategic moves, including its recent acquisition and expansion into the federal space.

For those looking to delve deeper into Cellebrite's financials and strategic outlook, InvestingPro offers additional insights and tips. There are currently 12 more InvestingPro Tips available for Cellebrite, which can be accessed at https://www.investing.com/pro/CLBT. To enhance your investment research, use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.